Logos Land Berlin und Land Brandenburg

Is this message not displayed correctly?
Please click here for the online version.

Headergrafik
1/2023
Photo Kai Uwe Bindseil
Dear Sir or Madam,

Since October 2022, our Cluster has a new spokesman. Prof. Dr. Heyo Kroemer, Chairman of the Board of Charité – University Medical Center Berlin, describes in our interview the current challenges for medicine and the healthcare industry and the potentials that arise from them.

One example of the current challenges is dealing with “Long COVID.” In the capital region there are a number of networks and initiatives that conduct research on this topic, exchange ideas and work to improve care for those affected. Our article provides an overview of the activities.

Part of the potential described by Prof. Kroemer is the “highly innovative work” that is possible in the region. Start-ups are an important component of this ecosystem. Learn how start-ups are supported here in our special article. Or – even better – get to know the actors directly on site. Good opportunities are offered again in the spring by DMEA (04/25-27/2023) or BIONNALE (05/16-17/2023)

We look forward to exchanging ideas with you!

Your
Dr. Kai Uwe Bindseil
Berlin Partner for Business and Technology 


Focus Topics

Meet us at...
Business News
Science and Technology News
Technology and Cooperation Offers

FocusTopics

Banner Focus Topics

Diverse challenges and opportunities

Interview: Prof. Dr. Heyo K. Kroemer, Chairman of the Board of Charité – University Medical Center Berlin and new spokesman of the Healthcare Cluster Berlin-Brandenburg

Long COVID in Berlin-Brandenburg – research, networks and engagement for better care

Research on Post and Long COVID is still in its infancy and so is knowledge about how to deal appropriately with the disease. At the same time, more and more affected people need help. This presents a challenge to healthcare as a whole. In Berlin and Brandenburg there are initiatives and networks at various levels that are trying to expand knowledge about the disease and to create structures for diagnostics and treatment. Last year’s Innovative Care Future Workshop of the Healthcare Cluster also addressed this topic.

This is how the capital region supports founders

Berlin is ahead of the rest of Germany in many segments when it comes to start-ups. Also in the life sciences sector, nowhere else in Germany are so many financing rounds completed as here. In addition to the quality of life which Berlin offers, numerous other factors play an important role in this success. Founders in Berlin can rely on support from a large network of offerings such as incubators, mentoring programs and premises. 

BCSE - Where Rare Diseases Are Not Rare 

February 28 was ‘rare disease day’ – an awareness day for all people who suffer from such a rare disease. An important contact point for them in the airport region Berlin Brandenburg is the Berlin Center for Rare Diseases (BCSE) of the Charité – Universitätsmedizin Berlin. Here, affected people of all ages find help, whether without or with an already established diagnosis. 
verlinktes Portraitfoto von Flavia Kruse

The tip from our relocation experts

Are you looking for qualified professionals in Berlin?

You can publish your job offers on our website. Right after registering you as
an employer on our Berlin focused job
platform you can start. Let us know once you have published a job add there – we then can promote your jobs on our social media channels on Facebook , LinkedIn and Instagram. Our job portal informs about any Berlin-based job and we promote this platform on national or international job fairs to any Berlin-interested professionals and talents.

Furthermore with the Business Immigration Service, we provide support in the application process for work and residence permits for foreign specialists, which you can adjust for your own needs. Talk to us as early in the process as possible, so that we can help organize the best possible support for the institutions involved.
If you need more suppport with any aspects of talents and recruitment - talk to us! We look forward to receiving your message.

Susan Kaffenberger
Berlin Partner for Business and Technology
Biotech | Pharma šŸ“§

MeetUsAt

Banner Meet us at

BIO Europe Spring

20.-22.03.2023 | Basel

DMEA 2023

25. - 27.04.2023 | Berlin

Visit us at Europe's largest digital health event!
  • Book your DMEA Business Meetings here
  • Get more information about our Berlin-Brandenburg Pavilion here
  • Register for our evening reception here

BIONNALE 2023

16.-17.05.2023 | Berlin
  • Sessions "New technologies changing the way we diagnose and cure diseases"
  • Matchmaking
  • Cooperation|Venture Track
  • Exhibition
  • Speed Lecture Award

Germany @ BIO
Boston/USA

05.-08.06.2023  | Boston, USA
Meet us at our German Pavilion!

Read more

MPS World Summit
2023 

26.-30.06.2023  | Berlin

2nd Microphysiological Systems World Summit
For more events in the life science region Berlin-Brandenburg click here.

BusinessNews

Banner Business News

OMEICOS Therapeutics announces expansion of OMT-28 clinical development program into primary mitochondrial diseases

OMT-28’s established safety profile, biomarker data, and funding secured from existing investors enable swift transition into a Phase II clinical study

Read more

ABL SA group acquires Berlin based Medtech company Humedics

ABL SA acquires the company Humedics Gmbh to extend the use of a robust, well-known, and CE-marked technology intended to be used for liver function measurement. Financial terms are not disclosed.

Read more

Glycotope cooperates with South Korean company Therabest to assess  cell product for development in triple negative breast cancer

Therabest and Glycotope to assess Therabest’s iPSC-derived NK cell product TB-100 in combination with Glycotope’s GT-00AxIL15 immuno-cytokine for development in triple negative breast cancer

Read more

Mesa Labs acquires Belyntic’s peptide purification business

Mesa Laboratories, Inc., a global leader in the design and manufacturing of critical quality control solutions for the pharmaceutical, healthcare, and medical device industries, today announced the acquisition of substantially all of the assets (other than current assets) and certain liabilities related to Belyntic GmbH’s (“Belyntic”) peptide purification business.

Read more

DSM chooses LabTwin to advance their digitalization strategy in Science & Innovation with the latest voice and AI solutions

DSM rolls out Labtwin's AI and voice powered digital lab assistant

Read more

ScienceAndTechnologyNews

Banner Science and Technology News

€60 million committed to establish AI and robotics in healthcare

EU project coordinated by Berlin Institute of Health at Charité (BIH) to test and validate innovative artificial intelligence (AI) and robotics solutions for the healthcare sector

Researchers of Max Delbrück Center develop a new method that is able to identify “zipcodes” that assign a destination to mRNAs

Researchers suspect that neurodegenerative diseases occur when messenger RNA (mRNA) goes astray in the neuron. With a new method, Marina Chekulaeva is able to identify “zipcodes” that assign a destination to mRNAs. She has now presented her method in the journal Nature Neuroscience.

Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) has discovered an unknown mechanism for how “starvation response” in body cells is triggered

Body cells burn off fat reserves when nutrient supply from food ceases. A team led by Professor Volker Haucke and Dr. Wonyul Jang from the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) has now discovered a previously unknown mechanism for how this “starvation response” is triggered, and what can inhibit it. The results have been published in the renowned international journal Science.

Read more

Study in Nature discovers causal mechanism behind rare hereditary diseases

Researchers from Charité – Universitätsmedizin Berlin, the Max Planck Institute for Molecular Genetics (MPIMG), and the University Hospital Schleswig-Holstein (UKSH) have investigated in detail how BPTA syndrome, an extremely rare hereditary condition, arises. A change in the charge of a protein disrupts cellular self-organization, resulting in a developmental disorder.

Green chemistry: BAM investigates pharmaceutical production without solvents and CO2 emissions


Read more

Max Delbrück Center's AI analysis of cancer mutations may improve therapy


Read more

Scientists of Max Planck Institute for Molecular Genetics have reconstructed chromosomes of patients with a high number of aberrations in their genome that potentially cause disease


Read more

Max Planck Director Prof. Dr. Peter Fratzl has been appointed honorary life member by the Chinese Chemical Society (CCS)


Read more

TechnologyAndCooperationOffers

Banner Technology and Cooperation Offers

Method and kit for early detection of preeclampsia


Read more

HDLBP overexpression promotes significant increased expression and secretion of proteins


Read more

High-level recombinant adeno-associated virus production


Read more

Oncolytic Coxsackievirus variante PD for treatment of cancer


Read more
For more news from the cluster healthcare industries click here.

Twitter Nutzername LinkedIn Firmenname
EDITOR | IMPRINT

This newsletter is operated by the Cluster Management Health Economics Berlin-Brandenburg HealthCapital.


Berlin Partner forĀ Business and Technology GmbH
Fasanenstrasse 85 | 10623 Berlin
Phone +49 30 46302-270
E-Mail: info (at) healthcapital.de

Commercial Registry Entry
Entered in the commercial registry of the Charlottenburg District Court,
Registration number: HRB 13072 BĀ 
VAT ID: DE 136629780

CEO: Dr. Stefan Franzke

Chairman of the Supervisory Board: Carsten Jung


Ā© 2023 Berlin Partner forĀ Business and Technology GmbH
Ā 
The newsletter of the Cluster healthcare industries Berlin-Brandenburg is a project of Berlin Partner for Business and Technology.

Ā 
Ā 
Logo THE GERMAN CAPITAL REGION
Ā 
You have been forwarded this newsletter and would like to subscribe?
Please click here.



You want to unsubscribe from the newsletter (to: unknown@noemail.com)? Please click here.